Hemodynamic effects of procainamide in patients with acute myocardial infarction and comparison with lidocaine

Richard R. Miller, General Hilliard, James E. Lies, Rashid A. Massumi, Robert Zelis, Dean T. Mason, Ezra A Amsterdam

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Comparative hemodynamic and electrocardiographic investigation of antiarrhythmic doses of procainamide and lidocaine was carried out in 19 patients with acute myocardial infarction or with severe left ventricular failure of other etiologies. In 12 patients in whom the standard recommended dosage of these agents was equally effective in abating ventricular tachyarrhythmias, there were no significant adverse hemodynamic and electrical effects or differences (p > 0.05) between relatively small salutary doses of lidocaine and procainamide after their intravenous administration in similar quantity and manner (100 mg in 3 min followed by 2 mg/min for 20 min). Furthermore, larger doses of procainamide (500 mg given 20 mg/min intravenously), which were also therapeutically beneficial in seven additional patients with acute myocardial infarction, caused no significant alteration (p > 0.05) in hemodynamic function. With the 500 mg dose, there was a small difference (p < 0.05) in the directional change of cardiac index which was dependent on the control values: the variable rose slightly in patients with normal indexes whereas it declined slightly in those with low values. Significant Q-T prolongation (p < 0.05) occurred with 500 mg of the agent; otherwise, there were no adverse electrocardiographic or untoward extracardiac effects. Thus, intravenous procainamide is equally effective in acute myocardial infarction and is a relatively safe alternative to lidocaine.

Original languageEnglish (US)
Pages (from-to)161-168
Number of pages8
JournalThe American journal of medicine
Volume55
Issue number2
DOIs
StatePublished - 1973

Fingerprint

Procainamide
Lidocaine
Hemodynamics
Myocardial Infarction
Tachycardia
Intravenous Administration

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Hemodynamic effects of procainamide in patients with acute myocardial infarction and comparison with lidocaine. / Miller, Richard R.; Hilliard, General; Lies, James E.; Massumi, Rashid A.; Zelis, Robert; Mason, Dean T.; Amsterdam, Ezra A.

In: The American journal of medicine, Vol. 55, No. 2, 1973, p. 161-168.

Research output: Contribution to journalArticle

Miller, Richard R. ; Hilliard, General ; Lies, James E. ; Massumi, Rashid A. ; Zelis, Robert ; Mason, Dean T. ; Amsterdam, Ezra A. / Hemodynamic effects of procainamide in patients with acute myocardial infarction and comparison with lidocaine. In: The American journal of medicine. 1973 ; Vol. 55, No. 2. pp. 161-168.
@article{3c41e030adef4a5fa8ce7ab2d9746628,
title = "Hemodynamic effects of procainamide in patients with acute myocardial infarction and comparison with lidocaine",
abstract = "Comparative hemodynamic and electrocardiographic investigation of antiarrhythmic doses of procainamide and lidocaine was carried out in 19 patients with acute myocardial infarction or with severe left ventricular failure of other etiologies. In 12 patients in whom the standard recommended dosage of these agents was equally effective in abating ventricular tachyarrhythmias, there were no significant adverse hemodynamic and electrical effects or differences (p > 0.05) between relatively small salutary doses of lidocaine and procainamide after their intravenous administration in similar quantity and manner (100 mg in 3 min followed by 2 mg/min for 20 min). Furthermore, larger doses of procainamide (500 mg given 20 mg/min intravenously), which were also therapeutically beneficial in seven additional patients with acute myocardial infarction, caused no significant alteration (p > 0.05) in hemodynamic function. With the 500 mg dose, there was a small difference (p < 0.05) in the directional change of cardiac index which was dependent on the control values: the variable rose slightly in patients with normal indexes whereas it declined slightly in those with low values. Significant Q-T prolongation (p < 0.05) occurred with 500 mg of the agent; otherwise, there were no adverse electrocardiographic or untoward extracardiac effects. Thus, intravenous procainamide is equally effective in acute myocardial infarction and is a relatively safe alternative to lidocaine.",
author = "Miller, {Richard R.} and General Hilliard and Lies, {James E.} and Massumi, {Rashid A.} and Robert Zelis and Mason, {Dean T.} and Amsterdam, {Ezra A}",
year = "1973",
doi = "10.1016/0002-9343(73)90164-2",
language = "English (US)",
volume = "55",
pages = "161--168",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Hemodynamic effects of procainamide in patients with acute myocardial infarction and comparison with lidocaine

AU - Miller, Richard R.

AU - Hilliard, General

AU - Lies, James E.

AU - Massumi, Rashid A.

AU - Zelis, Robert

AU - Mason, Dean T.

AU - Amsterdam, Ezra A

PY - 1973

Y1 - 1973

N2 - Comparative hemodynamic and electrocardiographic investigation of antiarrhythmic doses of procainamide and lidocaine was carried out in 19 patients with acute myocardial infarction or with severe left ventricular failure of other etiologies. In 12 patients in whom the standard recommended dosage of these agents was equally effective in abating ventricular tachyarrhythmias, there were no significant adverse hemodynamic and electrical effects or differences (p > 0.05) between relatively small salutary doses of lidocaine and procainamide after their intravenous administration in similar quantity and manner (100 mg in 3 min followed by 2 mg/min for 20 min). Furthermore, larger doses of procainamide (500 mg given 20 mg/min intravenously), which were also therapeutically beneficial in seven additional patients with acute myocardial infarction, caused no significant alteration (p > 0.05) in hemodynamic function. With the 500 mg dose, there was a small difference (p < 0.05) in the directional change of cardiac index which was dependent on the control values: the variable rose slightly in patients with normal indexes whereas it declined slightly in those with low values. Significant Q-T prolongation (p < 0.05) occurred with 500 mg of the agent; otherwise, there were no adverse electrocardiographic or untoward extracardiac effects. Thus, intravenous procainamide is equally effective in acute myocardial infarction and is a relatively safe alternative to lidocaine.

AB - Comparative hemodynamic and electrocardiographic investigation of antiarrhythmic doses of procainamide and lidocaine was carried out in 19 patients with acute myocardial infarction or with severe left ventricular failure of other etiologies. In 12 patients in whom the standard recommended dosage of these agents was equally effective in abating ventricular tachyarrhythmias, there were no significant adverse hemodynamic and electrical effects or differences (p > 0.05) between relatively small salutary doses of lidocaine and procainamide after their intravenous administration in similar quantity and manner (100 mg in 3 min followed by 2 mg/min for 20 min). Furthermore, larger doses of procainamide (500 mg given 20 mg/min intravenously), which were also therapeutically beneficial in seven additional patients with acute myocardial infarction, caused no significant alteration (p > 0.05) in hemodynamic function. With the 500 mg dose, there was a small difference (p < 0.05) in the directional change of cardiac index which was dependent on the control values: the variable rose slightly in patients with normal indexes whereas it declined slightly in those with low values. Significant Q-T prolongation (p < 0.05) occurred with 500 mg of the agent; otherwise, there were no adverse electrocardiographic or untoward extracardiac effects. Thus, intravenous procainamide is equally effective in acute myocardial infarction and is a relatively safe alternative to lidocaine.

UR - http://www.scopus.com/inward/record.url?scp=0015875554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015875554&partnerID=8YFLogxK

U2 - 10.1016/0002-9343(73)90164-2

DO - 10.1016/0002-9343(73)90164-2

M3 - Article

C2 - 4722854

AN - SCOPUS:0015875554

VL - 55

SP - 161

EP - 168

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 2

ER -